Genomic analysis of 2,658 Desulfovibrio strains links species-specific traits to inflammatory disease

A team of researchers has assembled the most comprehensive catalog of Desulfovibrio bacteria ever created—2,658 distinct genomes collected from patients and healthy people across 32 countries and spanning 90 different diseases. The work, published in Nature, reveals that these sulfur-metabolizing microbes are far more diverse than previously understood, and that specific strains carry traits directly linked to inflammatory bowel disease and colorectal cancer.

Desulfovibrio has long been suspected of playing a role in gut inflammation, but the evidence remained scattered and incomplete. To change that, researchers pulled genomes from multiple sources: they recovered 1,921 new high-quality genomes from 11,017 metagenomic samples across diverse populations in the Netherlands, China, Japan, Nepal, Tanzania, Germany, France, Israel, and the United States. They added another 578 genomes from a large reference database, 442 from public repositories, and crucially, they isolated and sequenced 24 live bacterial strains from patients with inflammatory bowel disease, colorectal cancer, and healthy individuals. After removing duplicates, they ended up with 2,658 unique genomes representing 37 species, most of them belonging to a single dominant species, Desulfovibrio elongatum, which made up 57 percent of the database.

What emerged from the genomic analysis was a picture of remarkable functional diversity. Different Desulfovibrio species carry wildly different sets of genes. Some species possess flagella—whip-like structures that allow bacteria to swim—while others do not. The flagellated species, including D. desulfuricans, D. legallii, and D. fairfieldensis, all carry genes for producing flagellin, the protein that makes up the flagellar filament. This matters because flagellin is a potent trigger for the human immune system. When flagellin binds to a receptor called TLR5 on intestinal cells, it sets off an inflammatory cascade. The researchers confirmed this experimentally: they grew D. desulfuricans and D. legallii in culture, collected their secretions, and exposed them to human immune cells engineered to report when TLR5 was activated. The activation was clear and measurable.

But the story grew more complex when the team moved to living tissue. They exposed mouse intestinal organoids—miniature gut structures grown from stem cells—to purified flagellin proteins from different Desulfovibrio species. One flagellin from D. desulfuricans, called Fla2DD_MS020, produced an unexpected result. Rather than triggering the typical inflammatory response seen with flagellins from other bacteria, it suppressed a critical immune tolerance pathway. Specifically, it downregulated genes involved in TGF-beta signaling, a pathway essential for maintaining immune balance in the gut. This suggests that certain Desulfovibrio strains may actively impair the immune system's ability to tolerate the microbiota, potentially tipping the balance toward chronic inflammation.

The second major finding concerns hydrogen sulfide production. Desulfovibrio bacteria are named for their ability to reduce sulfate, producing hydrogen sulfide as a byproduct. The researchers mapped out five different metabolic pathways by which these bacteria generate H2S. Most Desulfovibrio species, whether found in healthy or diseased individuals, encode the standard dissimilatory sulfate reduction pathway. But when the team looked specifically at inflammatory bowel disease samples, they found something striking: genes for tetrathionate metabolism—a pathway that allows bacteria to use a different sulfur compound as fuel—appeared almost exclusively in disease samples. These genes were present in multiple bacterial species, including Proteus mirabilis and Morganella morganii, not just Desulfovibrio. In inflammatory bowel disease patients, genes involved in taurine metabolism and cysteine degradation, both alternative routes to H2S production, were significantly more abundant than in healthy controls. The researchers also found that these genes were actively being expressed—the bacteria were not just carrying the genetic capacity but actually using it.

Geography and local adaptation also shaped the bacterial populations. When the researchers compared D. sp900319575 strains from East Asia with those from the Netherlands, they found distinct differences in gene content. East Asian strains carried more multidrug resistance genes, possibly reflecting higher antibiotic use in those regions. Dutch strains, by contrast, harbored more insertion sequences—mobile genetic elements that increase genome plasticity and may facilitate rapid adaptation. These geographic signatures suggest that Desulfovibrio populations evolve in response to local pressures, acquiring different functional capabilities depending on where they live.

The work also identified three potential new Desulfovibrio species that do not fit neatly into existing classifications, highlighting how much diversity remains undiscovered. The researchers tested 24 isolated strains for antibiotic resistance and found highly variable susceptibility patterns—some strains resistant to kanamycin, others to cephalosporins—suggesting that resistance emerges at the strain level, not uniformly across species. This variability matters for treatment: antibiotics that work against one Desulfovibrio strain may fail against another, even within the same species.

The comprehensive genomic resource now available opens new avenues for understanding disease. Rather than treating Desulfovibrio as a monolithic group, clinicians and researchers can now ask which specific strains are present in a given patient, what metabolic capabilities they carry, and whether those capabilities correlate with disease severity or progression. The identification of disease-specific traits—flagellin production, tetrathionate metabolism, urease synthesis—provides concrete targets for future intervention. Whether through selective antibiotics, probiotics that outcompete pathogenic strains, or therapies that block specific bacterial metabolites, the path forward is now clearer. The bacteria are no longer a black box.